source
- HHS commits up to $25M for ibogaine and other psychotropic drugs on Veteran's DayHHS announced an investment of up to $25 million for ibogaine and other rapid acting psychotropic medicines aimed at serious mental illnesses such as PTSD, unveiled on Veteran's Day. Up to $4.9 mi…
- Altimmune to discuss Phase 3 design for alcohol use disorder drug with FDAAltimmune is preparing to meet the FDA in December to discuss the design of a pivotal Phase 3 trial for its glucagon/GLP-1 dual receptor agonist pemvidutide. The Phase 2 RECLAIM study enrolled abo…